<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.   Common adverse reactions include increased ALT, nausea, increased AST, diarrhea , and vomiting  and serious adverse drug reactions are convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.
Ceritinib
Axitinib
Sunitinib
Baricitinib
Erdafitinib
Dacomitinib
Afatinib
Neratinib